Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 17Thoracic 12Gynecologic 11Genitourinary 11Other solid neoplasm 9Head & Neck 7Breast 5Dermatologic 3Endocrine 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1NET 1Lymphoid 1CNS 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
zimberelimab × Tumor-Agnostic × Clear all
NCT06759649 2026-02-27

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Compugen Ltd

Phase 1 Recruiting
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡